Currently, there are 167.12M common shares owned by the public and among those 166.05M shares have been available to trade.
The company’s stock has a 5-day price change of 27.64% and 11.08% over the past three months. ACAD shares are trading 21.31% year to date (YTD), with the 12-month market performance up to 49.80% higher. It has a 12-month low price of $13.40 and touched a high of $20.68 over the same period. ACAD has an average intraday trading volume of 1.79 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 40.58%, 38.50%, and 33.57% respectively.
Institutional ownership of Acadia Pharmaceuticals Inc (NASDAQ: ACAD) shares accounts for 103.76% of the company’s 167.12M shares outstanding.
It has a market capitalization of $3.73B and a beta (3y monthly) value of 0.54. The stock’s trailing 12-month PE ratio is 16.21, while the earnings-per-share (ttm) stands at $1.37. The company has a PEG of 16.05 and a Quick Ratio of 2.80 with the debt-to-equity ratio at 0.07. Price movements for the stock have been influenced by the stock’s volatility, which stands at 10.98% over the week and 6.05% over the month.
Earnings per share for the fiscal year are expected to decrease by -61.59%, and 61.31% over the next financial year.
Looking at the support for the ACAD, a number of firms have released research notes about the stock. Deutsche Bank stated their Hold rating for the stock in a research note on February 11, 2025, with the firm’s price target at $22. Guggenheim coverage for the Acadia Pharmaceuticals Inc (ACAD) stock in a research note released on January 03, 2025 offered a Neutral rating with a price target of $20. Raymond James was of a view on October 10, 2024 that the stock is Mkt Perform, while Morgan Stanley gave the stock Equal-Weight rating on August 07, 2024, issuing a price target of $28- $20. BMO Capital Markets on their part issued Outperform rating on June 27, 2024.
